Bio Green Med Solution, Inc. (BGMS)
NASDAQ: BGMS · Real-Time Price · USD
1.480
0.00 (0.00%)
At close: Dec 31, 2025, 4:00 PM EST
1.480
0.00 (0.00%)
Pre-market: Jan 2, 2026, 8:00 AM EST
Bio Green Med Solution Revenue
Bio Green Med Solution had revenue of $81.00K in the quarter ending September 30, 2025, with 305.00% growth. This brings the company's revenue in the last twelve months to $-611.00K. In the fiscal year ending March 31, 2025, Bio Green Med Solution had annual revenue of $1.92M with 2,134.38% growth.
Revenue (ttm)
$-611.00K
Revenue Growth
+2,134.38%
P/S Ratio
18.94
Revenue / Employee
$6,750
Employees
12
Market Cap
7.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.92M | 1.84M | 2,134.38% |
| Dec 31, 2024 | 86.00K | -2.03M | -95.94% |
| Mar 31, 2024 | 2.12M | 1.28M | 151.98% |
| Dec 31, 2023 | 840.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 150.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 843.00K | -1.10M | -56.64% |
| Dec 31, 2015 | 1.94M | 210.00K | 12.11% |
| Dec 31, 2014 | 1.73M | 650.00K | 59.96% |
| Dec 31, 2013 | 1.08M | 1.02M | 1,471.01% |
| Dec 31, 2012 | 69.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 686.00K | -225.00K | -24.70% |
| Dec 31, 2009 | 911.00K | 34.00K | 3.88% |
| Dec 31, 2008 | 877.00K | 748.00K | 579.84% |
| Dec 31, 2007 | 129.00K | -258.00K | -66.67% |
| Dec 31, 2006 | 387.00K | 31.00K | 8.71% |
| Dec 31, 2005 | 356.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BGMS News
- 7 weeks ago - Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - GlobeNewsWire
- 6 months ago - Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
- 6 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - GlobeNewsWire
- 6 months ago - CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT - GlobeNewsWire
- 6 months ago - Cyclacel Pharmaceuticals Announces Stock Split - GlobeNewsWire
- 6 months ago - Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock - GlobeNewsWire